Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010316
Filing Date
2025-05-14
Accepted
2025-05-14 16:45:22
Documents
64
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 813527
2 EX-31.1 ex31-1.htm EX-31.1 18750
3 EX-31.2 ex31-2.htm EX-31.2 18687
4 EX-32.1 ex32-1.htm EX-32.1 8957
5 EX-32.2 ex32-2.htm EX-32.2 8790
  Complete submission text file 0001641172-25-010316.txt   4532053

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE asbp-20250331.xsd EX-101.SCH 43954
7 XBRL CALCULATION FILE asbp-20250331_cal.xml EX-101.CAL 37672
8 XBRL DEFINITION FILE asbp-20250331_def.xml EX-101.DEF 194923
9 XBRL LABEL FILE asbp-20250331_lab.xml EX-101.LAB 311065
10 XBRL PRESENTATION FILE asbp-20250331_pre.xml EX-101.PRE 252190
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 549542
Mailing Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791
Business Address 194 CANDELARO DRIVE, #233 HUMACAO PR 00791 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41293 | Film No.: 25946614
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)